Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Cancer therapies addressing multi-billion markets

January 17, 2019 admin CEO Interview, Healthcare Comments Off on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Cancer therapies addressing multi-billion markets
James Oliviero, CEO

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

James Oliviero, CEO

 

 

 

 

 

 

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) CEO Interview with James F. Oliviero discussing clinical progress in company’s pipeline of cancer drugs, addressing multi-billion dollar markets. The company’s lead drug is in late stage clinical trials, with potential commercialization within next 3 years.

Investor Presentation

Checkpoint Presentation_CKPT_January 2019

 

 




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

September 9, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Sept. 09, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Newsmakers

Abeona Therapeutics (NASDAQ:ABEO) Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

April 20, 2018 admin Newsmakers Comments Off on Abeona Therapeutics (NASDAQ:ABEO) Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

NEW YORK and CLEVELAND, April 20, 2018 – Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European […]